Pemigatinib is a selective FGFR inhibitor in development for the treatment of patients with cholangiocarcinoma.
[1]. Arudra K, et al. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol. 2018 Oct;45(10):786-790.
















